⚠️ LEGAL DISCLAIMER
This information is for educational purposes only and does not constitute legal advice. Drug laws change frequently. Always verify current status with official government sources and consult a qualified legal professional before making any decisions. Psilocybin is illegal in most countries and violations can result in severe criminal penalties, including lengthy prison sentences, heavy fines, and — in some jurisdictions — the death penalty for supply offences.
How to Read This Guide: Colour-Coding System
Each country entry uses a status badge to give you an at-a-glance summary. The badges follow this key:
- GREEN Legal or officially decriminalised for specified uses
- YELLOW Partial / grey area / de facto tolerance — not formally legal but low enforcement or limited legal protections
- ORANGE Decriminalised — personal possession is not a criminal offence but may be an administrative offence (fine, civil sanction)
- RED Illegal — criminal offence with potential prosecution and imprisonment
- DARK RED Severely illegal — harsh penalties, zero tolerance, possible life sentence or death penalty for supply
Note: A "GREEN" or "ORANGE" badge does not mean psilocybin is safe or unregulated in that location. It reflects the legal status only. Always read the full entry for that country.
Comprehensive Legal Status Table
The table below covers 32 countries and jurisdictions. It was last reviewed in 2025–2026. Laws change — always cross-check with official government sources listed in the verification section below.
New: we've published dedicated deep-dive pages for 20 of the highest-interest countries below — each with its own detailed history, penalty breakdown, and verification sources. Look for the “Full country guide” link in the Key Notes column, or jump straight to a guide: United States, Canada, Netherlands, Portugal, Germany, Czech Republic, Brazil, Mexico, Australia, Jamaica, Spain, Austria, Switzerland, New Zealand, Ireland, Colombia, Uruguay, Denmark, Italy, Poland.
| Country / Jurisdiction | Legal Status | Possession Penalty | Supply / Trafficking Penalty | Key Notes | Last Verified |
|---|---|---|---|---|---|
| United States — Federal | RED | Up to 5 years federal prison + substantial fines for simple possession | Up to 20 years federal prison; life or death for very large quantity trafficking | Schedule I Controlled Substances Act. FDA Breakthrough Therapy designation exists for psilocybin in depression; clinical trial exemptions possible through IND application. Federal law supersedes state law but federal prosecution of state-legal activity is rare. Full country guide → | 2025 |
| USA — Oregon | GREEN | Personal possession decriminalised (Measure 110, 2020) — civil fine only | Supply outside licensed system remains a criminal offence under state law | Measure 109 (November 2020) created the first state-regulated supervised psilocybin services framework in the USA. Licensed service centres began operating from 2023 under the Oregon Health Authority. Clients must be 21+ and undergo a preparation session before a supervised dosing session. No prescription required. Federal law still applies. | 2025 |
| USA — Colorado | GREEN | Personal possession and gifting for adults 21+ legal under state law | Commercial sale outside licensed healing centres illegal; supply offences prosecuted | Proposition 122 (Natural Medicine Health Act), passed November 2022. Adults 21+ may legally possess, use, and gift psilocybin, psilocin, DMT, ibogaine, and mescaline (non-peyote). Licensed "healing centres" for supervised use licensed by the state from 2025. Gifting is legal; sale outside licensed centres is not. Federal law still applies. | 2025 |
| USA — California | YELLOW | Decriminalised in Oakland (2019), Santa Cruz (2020), San Francisco (2022) — city level only; statewide possession still criminal misdemeanour | Felony at state level outside decriminalised cities | Senate Bill 519, which would have decriminalised statewide, passed both chambers but was vetoed by Governor Newsom in 2023. City-level decriminalisation in Oakland, Santa Cruz, and San Francisco means the lowest-priority enforcement, but state criminal law still technically applies outside those cities. Legislature continues to pursue reform. | 2025 |
| USA — Washington State | YELLOW | Seattle and Port Townsend decriminalised at city level; statewide possession is a misdemeanour | Felony at state level | Seattle passed a resolution in 2021 making enforcement of natural psychedelic laws the "lowest law enforcement priority." Port Townsend followed. Senate Bill 5843 (2023) proposed statewide decriminalisation. The state legislature is actively debating a therapeutic access framework similar to Oregon's. Federal law still applies. | 2025 |
| USA — All Other States | RED | Varies: misdemeanour (up to 1 year) to felony (up to 5+ years) depending on state | Felony in most states; 1–10+ years depending on quantity and state law | Some cities (Denver CO was first to decriminalise in 2019; Ann Arbor MI; Somerville/Cambridge/Northampton MA; Detroit MI) have enacted local decriminalisation. Individual state laws vary considerably: Texas and Florida have stricter penalties than, say, Massachusetts. Always check state-specific statutes. Federal Schedule I classification applies everywhere in the US. | 2025 |
| United Kingdom | DARK RED | Up to 7 years imprisonment + unlimited fine | Up to life imprisonment + unlimited fine | Class A controlled drug under the Misuse of Drugs Act 1971. Both psilocybin mushrooms (fresh and dried) are Class A. Psilocybin spores are technically legal to purchase for microscopy as they contain no psilocybin, but germinating them to grow mushrooms is illegal. Research requires a Schedule 1 Home Office licence — expensive and difficult to obtain, though granted to institutions such as Imperial College London and King's College London. A 2023–24 Parliamentary inquiry examined reform options; no legislative change as of 2026. | 2025 |
| Netherlands | YELLOW | Dried mushrooms: fine + confiscation. Truffles: legal to possess and buy | Dried mushroom supply: criminal prosecution possible under Opium Act | Dried psilocybin mushrooms were banned in 2008 under List I of the Opium Act following media pressure after the death of a tourist. Fresh mushrooms occupy a legal grey area — technically "plant material" not specifically listed. However, the most significant loophole is that magic truffles (sclerotia of Psilocybe tampanensis, P. mexicana, P. atlantis) were never explicitly listed and remain fully legal to sell, possess, and use. Smartshops across the Netherlands openly sell truffles. Licensed psilocybin retreat centres using truffles operate legally throughout the country, particularly in Amsterdam and surroundings. Full country guide → | 2025 |
| Portugal | ORANGE | Civil offence only for up to 10-day personal supply; no criminal record | Trafficking remains a criminal offence; up to 12 years imprisonment | Portugal decriminalised personal possession of all drugs — including psilocybin — in 2001 under Law 30/2000. Possession of up to a 10-day personal supply is treated as a public health matter rather than a criminal one. Users caught with small amounts appear before a "Dissuasion Commission" (ComissĂŁo para a DissuasĂŁo da ToxicodependĂŞncia), which may impose fines, community service, or treatment referrals. No criminal record is created. Production and trafficking remain fully criminal. Portugal's model is widely cited internationally as a public health success; drug-related HIV infections and overdose deaths declined sharply after 2001. Full country guide → | 2025 |
| Czech Republic | ORANGE | Administrative offence for up to 40 dried mushrooms; fine up to CZK 15,000 (~€600) | Criminal offence; supply/trafficking up to 8 years imprisonment | Government Decree 467/2009 defines "small amounts" for personal use across various substances. For psilocybin mushrooms, possessing up to 40 dried mushrooms (approximately 5–6 grams) is an administrative rather than criminal offence. Larger amounts trigger criminal law. Cultivation is in a grey area — courts have differed on whether growing plants for personal use is "small amount possession." Supply and trafficking are prosecuted criminally. The Czech Republic has one of the most liberal drug possession policies in Central Europe. Full country guide → | 2025 |
| Germany | RED | Up to 5 years imprisonment; courts may divert small amounts to treatment | Up to 15 years for large-scale trafficking | Psilocybin remains on Anlage I of the Betäubungsmittelgesetz (BtMG) — the highest restriction, alongside heroin and cocaine. Germany legalised cannabis in 2024 (CanG), which raised hopes for psilocybin reform, but no concrete legislative proposals have been introduced as of 2026. For small personal amounts, prosecutors frequently divert cases to treatment or apply §31a BtMG (non-prosecution for minor offences). Research is possible via exemption from the Bundesinstitut fĂĽr Arzneimittel und Medizinprodukte (BfArM). Psilocybin-assisted therapy trials are underway at several German university hospitals. Full country guide → | 2025 |
| Austria | RED | Schedule I under SMG; personal use possession: diversion to treatment common (§§ 35–37 SMG) | Supply: 1–5 years; large scale: up to 15 years | Austria's Suchtmittelgesetz (SMG) places psilocybin in Schedule I (Suchtgift) with the highest restrictions. However, Austrian law has a strong diversion-to-treatment pathway: under §§ 35–37 SMG, prosecutors may waive prosecution for personal use in favour of treatment. This is commonly applied to small possession cases. Trafficking and supply are prosecuted criminally regardless. Research requires special authorisation from the Austrian Federal Office for Safety in Health Care (BASG). Vienna has seen growing interest in psilocybin therapy research. Full country guide → | 2025 |
| Switzerland | RED | Up to 3 years imprisonment or fine for possession | Up to 10 years for supply; aggravated trafficking up to 20 years | Psilocybin is classified under Schedule a (highest restriction) of the Betäubungsmittelgesetz (BetmG). Enforcement varies by canton — Bern and Basel tend toward lower enforcement for small personal amounts. Switzerland has a notable research tradition: the University of Basel (where Albert Hofmann worked) conducts psilocybin trials under the "Basel Protocol," and the Swiss Medical Committee for Psycholytic Therapy has operated for decades. Compassionate use requests can be made to SwissMedic. The country's harm-reduction infrastructure is among the world's best. Full country guide → | 2025 |
| Spain | YELLOW | Public possession/use: administrative penalty (fine); private use not criminalised | Supply: 3–9 years imprisonment | Psilocybin is illegal under Law 17/1967 in Spain. However, Spain's Constitutional Court has established that private cultivation for personal use occupies a grey area — not clearly criminalised. This logic, which underpins the "cannabis club" model, has inspired a degree of tolerance in private settings for psilocybin as well. Public possession and use carry administrative fines under the "Citizen Safety Law" (colloquially the "Gag Law"). Supply and trafficking are criminal. Several psilocybin retreat centres operate in Spain under the private-use rationale, though their legal status is contested. Full country guide → | 2025 |
| Canada | RED | Up to 3 years imprisonment | Up to 10 years for trafficking | Psilocybin is a Schedule III substance under the Controlled Drugs and Substances Act (CDSA). However, Canada has developed a meaningful exemption pathway: under Section 56 of the CDSA, the Minister of Health can grant individual exemptions. Since 2020, Health Canada has granted exemptions to terminally ill patients seeking psilocybin-assisted therapy, to licensed therapists and psychologists to use psilocybin in their practice, and to healthcare workers training in psychedelic therapy. The advocacy organisation TheraPsil has helped over 100 individuals obtain Section 56 exemptions. Several clinical trials are also underway. Reform legislation has been discussed but not passed as of 2026. Full country guide → | 2025 |
| Australia | GREEN (medical) / RED (recreational) | Recreational possession: up to 2 years (state-dependent); authorised medical use: legal | Supply/trafficking: up to 25 years depending on state | Australia became the first country in the world to formally approve psilocybin as a medicine. Effective 1 February 2023, the Therapeutic Goods Administration (TGA) rescheduled psilocybin from Schedule 9 (prohibited) to Schedule 8 (controlled medicine) for the treatment of treatment-resistant depression. Authorised Prescribers — psychiatrists approved by the TGA — can prescribe psilocybin to eligible patients. This is a landmark shift in global drug policy. Recreational possession and supply remain illegal under state and territory laws and attract criminal penalties. Prices for approved therapy are high (often AUD $10,000–$25,000 for a course), limiting access. Full country guide → | 2025 |
| Brazil | YELLOW | Mushrooms not explicitly listed; grey area — practical toleration common | Psilocybin as extracted compound may be prosecuted under broader narcotics laws | Brazilian drug law (Portaria SVS/MS 344/98 and its updates) does not specifically list Psilocybe mushrooms or psilocybin mushrooms by name. The isolated compound psilocybin could theoretically be prosecuted under a broader "analogues" provision, but in practice, mushrooms are not targeted. Retreat centres and ceremonial use are widespread and operate openly, particularly in states such as Minas Gerais and in the Amazon region where indigenous ayahuasca traditions (separately explicitly legal) normalise plant-based ceremony. Brazil's regulatory position remains a legal grey area rather than explicit legalisation. Full country guide → | 2025 |
| Jamaica | GREEN | Legal — no restrictions on possession | Legal — no restrictions on supply or sale | Jamaica's Dangerous Drugs Act does not list psilocybin mushrooms. They are completely legal to possess, use, cultivate, buy, and sell in Jamaica with no criminal or civil penalty. This makes Jamaica one of the world's premier destinations for psychedelic tourism. Numerous established retreat centres — including Atman Retreat, MycoMeditations, and others — operate openly and legally. Many are staffed by internationally trained therapists and follow evidence-based protocols. Note: while legal in Jamaica, returning home with mushrooms or psilocybin is illegal in almost every other country — customs and import law at your destination applies. Full country guide → | 2025 |
| Mexico | YELLOW | Federal law: Schedule I; urban possession illegal. Oaxaca: de facto tolerance for ceremonial context | Supply: criminal prosecution under federal Ley General de Salud | Mexican federal drug law lists psilocybin as Schedule I. However, Article 2 of the General Health Law and indigenous rights protections under CNDH guidelines recognise the traditional Mazatec use of psilocybin mushrooms (hongos sagrados) in spiritual and healing ceremonies in Oaxaca state, particularly around the Sierra Mazateca region (Huautla de JimĂ©nez). State and local authorities in Oaxaca de facto tolerate mushroom retreats and tourism. In Mexico City and other urban centres, possession is illegal and enforcement is less predictable. The distinction between "ceremonial use" and "tourism" is legally grey. Full country guide → | 2025 |
| New Zealand | RED | Up to 6 months imprisonment + NZ$500 fine for small personal amounts; up to 2 years for larger amounts | Up to 14 years imprisonment | Psilocybin is a Class A controlled drug under the Misuse of Drugs Act 1975 — the highest restriction. Small personal amounts carry the lowest penalties but prosecution still possible. New Zealand's 2020 referendum on cannabis legalisation narrowly failed (46% in favour), dampening the legislative appetite for broader drug reform in the short term. Research is possible under a ministerial exemption. The Drug Foundation NZ advocates harm-reduction approaches. Enforcement is generally proportionate to quantity. Full country guide → | 2025 |
| Japan | DARK RED | Up to 7 years imprisonment | Import/export: up to 10 years; large-scale trafficking: up to life | Psilocybin and psilocin were added to Japan's Narcotics and Psychotropics Control Law in 2002. Japan has extremely strict drug enforcement: arrests, prosecutions, and convictions are nearly universal once charges are brought. Foreign nationals convicted face deportation after serving sentences. Mushroom spores are theoretically unscheduled but attempting to import or cultivate them would create serious legal exposure. Japan conducts almost no clinical research into psilocybin. Do not travel to Japan with any psilocybin-related materials under any circumstances. | 2025 |
| Thailand | DARK RED | Up to 15 years imprisonment | Import/export: life imprisonment; large quantity supply: death penalty possible | Psilocybin mushrooms are a Category 5 narcotic under the Narcotics Act B.E. 2522 (1979, as amended). Despite Thailand legalising cannabis in 2022 (then rowing back in 2024), psilocybin has not been part of that reform debate. "Magic mushrooms" are openly offered in some tourist areas (particularly Koh Samui and Koh Phangan), but this is entirely illegal and tourists are targeted by enforcement and scams. Penalties are severe and the Thai prison system is notoriously harsh for foreign drug offenders. Thailand is classified DARK RED: avoid absolutely. | 2025 |
| Ireland | DARK RED | Up to 7 years imprisonment; unlimited fine for supply-level possession | Unlimited imprisonment (life) + unlimited fine | Psilocybin is a Schedule 1 controlled drug under the Misuse of Drugs Acts 1977–2016, equivalent to Class A in the UK. Ireland has one of the strictest drug enforcement regimes in Western Europe. Possession of any amount can result in up to 7 years (possession with intent to supply carries the unlimited maximum). Ireland's Citizens' Assembly on Drugs has examined reform (2023 report recommended decriminalisation), but no legislation has been passed as of 2026. Research remains highly restricted. Full country guide → | 2025 |
| France | RED | Up to 1 year + €3,750 fine (personal); enforcement varies; forfait dĂ©lictuel flat fine often applied | Up to 10 years + €7.5 million fine | Psilocybin is classified as a stupĂ©fiant (narcotic) under French law. A 2020 law introduced a fixed-penalty notice (forfait dĂ©lictuel) of €200 for simple drug use as an alternative to prosecution, making enforcement more administrative in practice for minor possession. However, the offence remains criminal on the books. France has several active psilocybin clinical research programmes. Macron's government commissioned a report on drug policy reform in 2023; possession decriminalisation remains politically contested. | 2025 |
| Italy | ORANGE | Personal use: administrative sanctions (driving licence suspension, passport delays, etc.); no criminal record for small amounts | Supply: 6–20 years imprisonment | Presidential Decree 309/1990 (Testo Unico sulle droghe) places psilocybin in Table I (most restricted). However, Constitutional Court rulings have established that personal use — possession for one's own consumption — is not a criminal offence but attracts administrative sanctions such as temporary suspension of driving licence, firearm licence, or passport. The distinction between "personal use" and "supply intent" is determined by quantity and circumstances. Small amounts found by police typically result in a prefect's administrative warning and possible licence suspension. Research exemptions exist through the Italian Medicines Agency (AIFA). Full country guide → | 2025 |
| Russia | DARK RED | Up to 3 years; "significant amount": up to 10 years; "large amount": up to 15 years | Up to 20 years or life for organised trafficking | Psilocybin is a List I controlled substance under Federal Law No. 3-FZ on Narcotics and Psychotropic Substances. Russian drug law defines escalating penalties based on quantity thresholds. Enforcement is strict and the criminal justice system provides few procedural protections. There is no research, clinical trial, or therapeutic exemption pathway in practice. The political climate makes reform extremely unlikely. Foreign nationals face deportation in addition to imprisonment. | 2025 |
| India | DARK RED | Small quantity: 6 months–1 year + fine; intermediate: up to 10 years + fine; commercial quantity: 10–20 years + fine | Commercial trafficking: 10–20 years; repeat offences: up to life | Psilocybin is controlled under Schedule I of the Narcotic Drugs and Psychotropic Substances Act 1985 (NDPS Act). India's NDPS Act is notoriously strict with high mandatory minimums and few diversion options. "Small quantity" vs "commercial quantity" thresholds determine sentencing bands. Bail is difficult to obtain for commercial quantity charges. The traditional use of Soma (possibly a psychoactive mushroom) in Vedic culture is of historical interest but provides no modern legal protection. Research is theoretically possible under CDSCO authorisation but essentially uncharted. | 2025 |
| China | DARK RED | Up to 3 years for possession; large amounts: up to 15 years | Large-scale trafficking: death penalty possible | Psilocybin is a Schedule I (most restricted) psychotropic substance under Chinese Criminal Law and the Regulations on the Control of Narcotic Drugs and Psychotropic Substances. China maintains a zero-tolerance approach to illicit drug use, with mandatory drug testing programs in some regions. Death penalty for drug trafficking — including psychedelics — has been carried out historically for large quantities. Foreigners are not exempt from capital punishment for serious drug crimes. There is no therapeutic or research pathway for psychedelics outside strictly controlled government-sanctioned research. Avoid absolutely. | 2025 |
| Colombia | YELLOW | Mushrooms not explicitly named in national schedules; "dosis personal" doctrine tolerates small personal-use quantities | Supply/trafficking prosecuted under general narcotics law; no psilocybin-specific case law confirmed | Law 30 of 1986 lists cocaine, cannabis, and other named substances, but psilocybin mushrooms are not clearly and specifically scheduled. The Constitutional Court's "dosis personal" (personal dose) doctrine (Sentencia C-221 of 1994 and later rulings) means small personal-use possession is unlikely to be criminally prosecuted, and mushrooms are sold semi-openly in some tourist areas. This is a legal gray area, not a formal legalisation — we could not confirm how courts would treat larger-scale supply or cultivation cases. Full country guide → | 2026 |
| Uruguay | YELLOW | Long-standing non-criminalisation of personal-use possession (judge assesses quantity/circumstances); no dedicated psilocybin framework | Supply/trafficking/production for sale remains a criminal offence | Uruguay is best known for fully legalising and regulating recreational cannabis (Law 19.172, 2013), but that reform did not extend to psilocybin. A separate, older principle in Uruguayan law (Decree-Law 14.294, 1974) has long held that possession purely for personal consumption is not criminally punished, which likely extends informally to psilocybin — however, mushrooms have no dedicated legal retail or cultivation-club framework the way cannabis does. Not formally "legal," but personal use is unlikely to be prosecuted. Full country guide → | 2026 |
| Denmark | RED | Criminal offence; small first-time personal amounts often result in a fine or warning rather than imprisonment | Criminal offence; supply and larger quantities prosecuted more severely | Psilocybin and psilocin are controlled under Denmark's executive order on euphoriant substances. Copenhagen's City Council voted in 2018 to pursue a pilot decriminalisation of personal drug possession, but this required national government approval, and we could not confirm it became binding national policy — treat any claim that Denmark or Copenhagen has "decriminalised drugs" with caution. Danish universities and hospitals participate in psilocybin-assisted therapy research under national medicines-agency exemptions. Full country guide → | 2026 |
| Poland | RED | Up to ~3 years imprisonment under Article 62 of the 2005 Act on Counteracting Drug Addiction (basic offence) | Production/trafficking prosecuted more severely, commonly cited up to ~10 years for aggravated cases | Psilocybin and psilocin are group I-P controlled substances under Poland's Ustawa o przeciwdziaĹ‚aniu narkomanii (2005, as amended). Reform proposals to introduce a Czech-style "small quantity" administrative exception have been debated in the Sejm, but we could not confirm whether such a reform has been enacted as of 2026 — treat Poland's decriminalisation status as an open question pending direct verification of current statute. Full country guide → | 2026 |
Travel Risk Considerations
International travel significantly complicates psilocybin's legal picture. Your home country's laws do not follow you abroad, and the laws of your destination country apply from the moment you land — and in some cases, even before you arrive.
Never Assume Legal Status Transfers
A common — and potentially catastrophic — mistake is assuming that because psilocybin is decriminalised or tolerated in your home country, it is therefore acceptable at your destination. Each country is sovereign in its drug law. A Portuguese national travelling to Japan carries no legal protection from Portuguese decriminalisation; they are subject to Japanese narcotics law. Similarly, an Oregon resident who uses psilocybin legally at a state-licensed service centre cannot bring any remaining material on an international flight without violating federal law (the flight, the aircraft, and the airport all fall under federal jurisdiction).
Airport and Border Searches
International airports are typically federal or national jurisdiction, meaning that even in US states with local decriminalisation, the Transportation Security Administration (TSA) and Customs and Border Protection (CBP) operate under federal law. Any psilocybin mushrooms, spores, or related materials found at security screening or customs — including in checked baggage — can result in federal charges. Drug-detection dogs are trained to detect psilocybin mushrooms in some jurisdictions. Note that spores are technically legal in many places (they contain no psilocybin before germination), but carrying them across international borders for the purpose of cultivation may still be treated as drug trafficking by customs authorities who do not make this distinction.
Psychedelic Tourism Destinations
Jamaica, the Netherlands (truffles), and Mexico/Oaxaca are common destinations for legally or quasi-legally accessing psilocybin experiences. Key considerations for travellers:
- Jamaica: Fully legal in Jamaica, but returning to most home countries with any psilocybin materials — including fresh or dried mushrooms — constitutes drug importation. Do not attempt to bring anything back. The retreat experience itself is legal; the return customs crossing is not.
- Netherlands (truffles): Purchasing and consuming truffles is legal in the Netherlands. Crossing into Germany, Belgium, France, or the UK with truffles is illegal in each of those countries. Do not carry truffles across Dutch borders.
- Mexico/Oaxaca: Informal tolerance exists for ceremonial use in Oaxaca, but this is not a formal legal protection. Penalties for non-indigenous tourists caught by federal law enforcement outside the ceremonial context can be severe. The distinction between "participant in an indigenous ceremony" and "drug tourist" is subjectively applied.
Drug Interactions and Medications
If you are travelling with prescription medications that interact with psilocybin (such as SSRIs, MAOIs, or lithium), carry documentation of your prescription. In some strict-enforcement countries, certain legal medications can cause complications at customs. This is a separate issue from psilocybin legality but relevant to overall safety.
Visa and Entry Implications
Some countries — notably the United States, Australia, Canada, Japan, and the UK — ask on visa applications whether you have ever been convicted of a drug offence. A conviction (not just arrest) in any country can result in visa denial or entry refusal. Portugal's decriminalisation means no criminal record is created there; however, a criminal conviction in a country with harsher laws can have long-term travel consequences. If you have any prior drug conviction, consult an immigration lawyer before travelling to countries with strict entry requirements.
How to Verify Current Legal Status
Given how rapidly drug laws change, the information in this guide — however carefully researched — may be out of date. Here is a reliable framework for verifying current legal status before making any decisions.
Official Government Sources
These are the most authoritative sources and should always be your first check:
- United States: DEA Drug Scheduling — dea.gov; state-level law requires checking individual state statutes via official state legislature websites.
- United Kingdom: Home Office Drugs Penalties page — gov.uk
- Canada: Health Canada Controlled Substances — canada.ca
- Australia: TGA Scheduling — tga.gov.au
- Netherlands: RIVM (National Institute for Public Health) — rivm.nl
- EU countries generally: Individual member state health ministries and medicines agencies; links are available via the European Medicines Agency (EMA).
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
The EMCDDA maintains a regularly updated database of drug laws across all EU member states plus Norway, Turkey, and some other countries. Their Drug Law Profiles section at emcdda.europa.eu provides country-by-country summaries of schedules, penalties, and recent legislative changes. This is an excellent starting point for European country verification.
Civil Society and Harm-Reduction Sources
- Erowid Law Vault (erowid.org/law): Long-running community resource with country and US-state-by-state legal summaries. Generally well-maintained but not a substitute for official sources — verify independently before acting on any information.
- NORML International (norml.org): Focuses primarily on cannabis but often covers broader drug policy and contains useful international comparisons.
- Transform Drug Policy Foundation (UK): Publishes policy analysis and tracks reform legislation across multiple jurisdictions.
- Drug Policy Alliance (US): Tracks state-level legislative changes in the United States in near-real time.
When to Consult a Lawyer
Online resources — including this guide — are no substitute for qualified legal advice when real-world decisions are at stake. You should consult a lawyer if you: are considering travelling internationally with any psilocybin-related materials; are involved in or considering participating in a psilocybin business or clinical trial; have been arrested or charged with any drug offence; or want to establish a legal defence strategy in any jurisdiction. Many countries have bar association referral services that can connect you with a drug law specialist.
Research Exemptions: How to Access Psilocybin Legally for Scientific Purposes
In most countries with strict drug laws, an exemption pathway exists for bona fide scientific and clinical research. While these pathways are not available to the general public, they are important to understand as they underpin the clinical trial boom that is driving drug policy reform worldwide.
United States: DEA Schedule I Researcher Registration
Researchers wishing to work with Schedule I substances including psilocybin in the US must obtain a DEA Schedule I Researcher Registration (Form 225). This requires institutional affiliation (typically a university or hospital), a DEA-registered site with approved security measures, an FDA Investigational New Drug (IND) application for clinical trials, and IRB (Institutional Review Board) approval. The FDA has granted Breakthrough Therapy Designation to psilocybin for treatment-resistant depression (COMPASS Pathways, 2018) and major depressive disorder (Usona Institute, 2019), streamlining some regulatory steps. As of 2025, dozens of Phase 2 and Phase 3 trials are ongoing in the US.
United Kingdom: Home Office Schedule 1 Licence
In the UK, psilocybin research requires a Schedule 1 licence from the Home Office in addition to standard research governance approvals. These licences apply to both the institution and the individual researchers named. They cover manufacture, supply, possession, import, and export — each of which requires specific endorsement. The application process is demanding, costly, and slow, and has been widely criticised by researchers as a barrier to progress. Prominent UK research groups including those at Imperial College London and King's College London have navigated this process, but smaller institutions often cannot afford to.
Health Canada Section 56 Exemptions
Under Section 56 of Canada's CDSA, the federal Minister of Health can grant individual exemptions from drug law for medical or scientific purposes. These have been used to allow: clinical trial participants to receive psilocybin; licensed healthcare providers to administer psilocybin in therapeutic settings; and palliative care patients facing end-of-life distress to access psilocybin therapy. The process is individual-by-individual, which is burdensome, but TheraPsil and similar organisations help navigate it. Researchers conducting clinical trials also apply for Section 56 exemptions alongside standard Health Canada Clinical Trial Application (CTA) processes.
EU Country-Specific Pathways
EU member states each maintain their own national authorisation processes for Schedule I research. In Germany, the BfArM grants exemptions; in the Netherlands, the CCMO (Central Committee on Research Involving Human Subjects) governs clinical trials and the Ministry of Health grants Schedule I research permissions; in Switzerland, SwissMedic authorises trials. The European Medicines Agency (EMA) is not the primary body for psychedelic trials — these remain under national authority — but EMA guidance on trial design applies once a product reaches later-stage development.
Industry-Sponsored Trials
COMPASS Pathways (London/New York, NASDAQ: CMPS) and Usona Institute (US non-profit) are the leading industry sponsors of psilocybin clinical trials. COMPASS holds the world's largest psilocybin trial dataset. Other companies including Cybin, MindMed, atai Life Sciences, and Field Trip Health are also running trials in multiple jurisdictions. Participation in an industry-sponsored trial is one of the few legal pathways for members of the public in restrictive countries to access psilocybin in a supervised medical context. ClinicalTrials.gov lists ongoing trials by location.
Recent Legal Changes and Emerging Trends 2023–2026
The psilocybin legal landscape has shifted more in the past three years than in the previous three decades. Here is a summary of the most significant developments and the trajectory they suggest.
Australia TGA Rescheduling (February 2023)
The TGA's decision to reschedule psilocybin to Schedule 8 for treatment-resistant depression is the most significant regulatory change in the drug's history. It is the first time any national drug regulator has formally approved psilocybin as a medicine. The initial authorised prescriber list is small, therapy is expensive, and access is limited, but the precedent is historic. Other national regulators — including the UK's MHRA and Health Canada — are watching the Australian rollout closely.
Oregon Measure 109 Rollout (2023–2025)
Oregon's regulatory framework for psilocybin service centres, created by Measure 109, was finalised by the Oregon Health Authority in 2022 and the first licences issued in 2023. By mid-2025, multiple licensed service centres operate in Oregon, primarily in the Portland and Eugene areas. The model requires clients to complete a preparation session before a supervised dosing session, with an optional integration session. This is a US-first and the most closely watched domestic policy experiment in psychedelics.
Colorado Proposition 122 Rollout (2023–2025)
Colorado's Proposition 122 created both a personal use right (possession and gifting for adults 21+) and a licensed "healing centre" framework. Personal possession became legal in 2023; the first licensed healing centres began operating in 2025. Colorado's framework is broader than Oregon's — it covers psilocybin, psilocin, DMT, ibogaine, and non-peyote mescaline — and allows gifting as well as supervised use. The state's Natural Medicine Advisory Board continues to develop rules for new substances and use cases.
Germany: Cannabis Legalisation and Psilocybin Implications (2024)
Germany's CanG (Cannabis Act), which came into force in April 2024, legalised personal cannabis use and possession for adults. While psilocybin was not part of that legislation, the political and cultural climate it created is relevant: Germany has demonstrated willingness to break with longstanding drug prohibition, several German parliamentary members have called for extending reform to other substances, and psilocybin research at German universities has increased. No concrete timeline for psilocybin-specific legislation exists as of 2026, but Germany is considered a near-term candidate for therapeutic access reform in Europe.
UK Parliamentary Inquiry 2023–2024
The UK Parliament's Science and Technology Committee conducted an inquiry into psychedelic research in 2023–2024, taking evidence from researchers, clinicians, and policy experts. The committee's report called for a review of the Schedule 1 licensing burden for psilocybin research, though it stopped short of recommending decriminalisation or therapeutic access. The report's influence on the current Labour government's drug policy agenda remains to be seen. Campaign groups including Drug Science and the Centre for Psychedelic Research at Imperial College London continue to advocate for reform.
WHO Expert Committee on Drug Dependence (ECDD)
The World Health Organization's ECDD reviews the scheduling status of psychoactive substances under international conventions. Psilocybin is currently controlled under the 1971 Convention on Psychotropic Substances (Schedule I). A critical review by the ECDD could lead to a recommendation for rescheduling — reducing the international barriers to research and therapeutic access — but as of 2026, no formal critical review of psilocybin has been completed. Advocacy from scientific and medical organisations is increasing pressure for such a review.
The Therapeutic Access Model as a Global Trend
The emerging consensus in countries where reform is advancing is not full legalisation (as with cannabis in some jurisdictions) but therapeutic access: creating regulated frameworks for supervised clinical or retreat use, while maintaining criminal prohibitions on recreational use and uncontrolled supply. Australia, Oregon, Colorado, Canada (Section 56 pathway), and the Netherlands (truffles + retreats) all represent variations on this model. This is likely the near-term trajectory for UK, German, and other European reform efforts.
Frequently Asked Questions
Is psilocybin legal anywhere in the world for recreational use?
Jamaica is currently the only country where psilocybin mushrooms are entirely unregulated — there is no law against possessing, using, growing, buying, or selling them. The Netherlands does not schedule psilocybin truffles (sclerotia), making truffle use effectively legal, though within a more complex regulatory context than Jamaica. Brazil occupies a legal grey area where mushrooms are not explicitly listed in drug schedules. No country has formally "legalised" psilocybin in the way that Canada, Uruguay, and some US states have legalised cannabis — even Oregon and Colorado's frameworks restrict use to supervised or personal settings, not open commercial sales.
What is the difference between decriminalisation and legalisation?
Legalisation means a substance is permitted under the law — either with or without regulation. Decriminalisation means that personal possession is no longer treated as a criminal offence, but the substance is not technically "legal" — supply, production, and trafficking typically remain criminal, and administrative penalties (fines, treatment referrals) may still apply for possession. Portugal decriminalised all drugs in 2001: possession is a civil matter, not a crime, but producing or selling drugs is still fully criminal. Oregon went further by creating a legal regulated supply chain for psilocybin services, which is a form of limited legalisation. The practical difference matters enormously: in a decriminalised system, you may escape a criminal record but you are still at risk of civil penalties and the substance has no quality assurance or harm-reduction regulation.
Can I travel internationally after legally using psilocybin at an Oregon service centre?
Yes — using psilocybin at an Oregon-licensed service centre is legal under Oregon state law. This does not create a criminal record. However: (1) the activity is still technically a federal offence (Schedule I), though federal prosecution of state-legal activity is rare; (2) you cannot bring any psilocybin materials out of Oregon across state or international lines, as interstate transport is a federal offence; (3) if a foreign country's visa application asks about drug convictions, state-legal psilocybin use creates no conviction to disclose; (4) your experience at a service centre is confidential medical-style information and is not reported to any federal database. In practical terms, most travellers have nothing to disclose. If in doubt, consult an immigration lawyer specific to your destination country.
Are psilocybin spores legal to buy and sell?
In many jurisdictions, yes — with important caveats. Psilocybin mushroom spores contain no psilocybin or psilocin, which are the scheduled compounds. As a result, spores are technically unscheduled in many countries including most US states (except California, Georgia, and Idaho, which have explicitly banned spore possession), the UK, Canada, and others. They are widely sold online for "microscopy and educational purposes." However, purchasing spores with the intent to cultivate mushrooms is considered drug production in virtually every jurisdiction — intent can be inferred from context (buying spore syringes alongside substrate and grow equipment, for example). In Germany and the Netherlands, spores are explicitly unscheduled, as they are in most EU countries. Always verify the specific law in your jurisdiction, and understand that "spores are legal" does not mean "cultivating with those spores is legal."
What happens if I am caught with psilocybin mushrooms at a UK airport?
UK airports are subject to UK law — specifically the Misuse of Drugs Act 1971. Psilocybin mushrooms (fresh or dried) are Class A controlled drugs. Being found with them at a UK airport (whether arriving, departing, or in transit) can result in arrest, detention, and criminal charge for possession of a Class A drug. The maximum penalty for possession is 7 years' imprisonment plus an unlimited fine, though first-time offenders caught with small amounts for personal use more commonly receive a caution, conditional discharge, or community order rather than imprisonment. However, a caution or conviction will appear on a CRB/DBS check and can affect employment, especially in regulated professions. Supply or trafficking charges — which can be inferred from larger quantities, packaging, or cash — carry a maximum of life imprisonment. Do not attempt to bring psilocybin mushrooms through any UK airport.
Is it legal to grow psilocybin mushrooms at home?
In nearly all countries, no. Cultivation of psilocybin mushrooms is treated as production or manufacturing of a controlled substance, which is typically prosecuted more seriously than simple possession. In the US, home cultivation is a federal felony regardless of state decriminalisation policies. In the UK, cultivating mushrooms is treated as production of a Class A drug and carries the supply penalty (up to life). Spain's grey area around private cultivation for personal use is the main exception in Europe, based on Constitutional Court reasoning, but this is an uncertain and contested protection. Jamaica is the clear exception: home cultivation is entirely legal. In decriminalised jurisdictions like Portugal, the decriminalisation covers possession of personal amounts — production/cultivation is still criminal. The Czech Republic and Italy similarly decriminalise possession but not cultivation.
What is a Health Canada Section 56 exemption and how do I apply?
A Section 56 exemption under Canada's Controlled Drugs and Substances Act allows the Minister of Health to exempt individuals or classes of individuals from specific provisions of the Act for medical or scientific purposes. For psilocybin, these exemptions have been used to allow terminally ill patients, licensed therapists, and training healthcare professionals to access psilocybin legally. To apply, an individual submits a detailed application to Health Canada explaining the medical justification, their healthcare provider's support, and the specific activity requested. The organisation TheraPsil (therapsil.ca) specialises in navigating this process and has helped many patients successfully obtain exemptions. The process is not quick — it typically takes several months — and requires a sponsoring healthcare professional. Patients most commonly successful have been those with life-threatening diagnoses and treatment-resistant conditions.
How does Australia's TGA rescheduling work in practice?
Australia's Therapeutic Goods Administration (TGA) rescheduled psilocybin from Schedule 9 (prohibited) to Schedule 8 (controlled medicine) effective 1 February 2023, specifically for use in treating treatment-resistant depression. Under this framework, only psychiatrists who have been approved as "Authorised Prescribers" by the TGA can prescribe psilocybin to eligible patients. As of mid-2025, there are fewer than 100 authorised prescribers in Australia. The therapy is conducted in a clinic with trained support staff and typically involves two or three supervised dosing sessions combined with psychotherapy. It is not covered by Medicare and costs AUD $10,000–$25,000 for a full course, meaning access is largely limited to those who can pay privately. MDMA was rescheduled at the same time for PTSD treatment. Recreational possession and supply of psilocybin remain illegal under state law.
Which countries are most likely to reform psilocybin laws next?
Based on current legislative activity, parliamentary inquiries, and regulatory reform signals as of 2026, the countries most likely to introduce significant psilocybin reforms in the near term are: Germany (following cannabis legalisation in 2024, with growing political and academic support for therapeutic access); New Zealand (where a Drug Foundation-backed harm reduction movement has government attention, though the 2020 cannabis referendum failure was a setback); United Kingdom (parliamentary inquiry evidence sessions in 2023–24, growing MHRA interest in regulated therapy, strong research base at Imperial and KCL); Switzerland (long research tradition, compassionate access pathways already exist, political culture of pragmatism); and Ireland (Citizens' Assembly on Drugs 2023 recommended decriminalisation). None of these represent certainty — drug policy reform is unpredictable and subject to political reversals.
Can employers test for psilocybin use?
Psilocybin is not included in standard 5-panel or 10-panel workplace drug tests, which typically screen for cannabis, cocaine, amphetamines, opioids, and PCP. Psilocybin and psilocin metabolise rapidly — typically within 24–48 hours — and are not retained in hair follicles at detectable levels in the way cannabis is. Specialised extended drug panels can test for psilocybin, and some employers in safety-sensitive industries (aviation, nuclear, transportation) use expanded testing. In jurisdictions where psilocybin use is still illegal (even recreationally), a positive test could be grounds for termination and potentially for referral to law enforcement, depending on employment contract and jurisdiction. In Oregon and Colorado, where psilocybin use is more legally protected, employment law regarding psilocybin is still evolving — employers may still be permitted to maintain drug-free workplace policies even for state-legal activities, similar to how some employers treat cannabis.